All Stories

  1. Addiction, Agency, and the Limits of Choice: Involuntary Care as a Stress Test for Psychiatric Ethics
  2. Defining Cannabis Use Disorder in Administrative Health Data: A Systematic Review of Case Definitions and Validation Approaches
  3. Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems
  4. Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era
  5. Characteristics of Adults With Addictions and Mental Health Problems Who Have Experienced Homelessness: A Population-Based Study From Alberta, Canada: Caractéristiques des adultes aux prises avec des problèmes de dépendance et de santé mentale et ayant...
  6. Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders
  7. Emerging pharmacological strategies for the treatment of cannabis use disorder
  8. The Unseen Addiction: Improving Surveillance and Governance of Medical Cannabis in Canada
  9. Limitations and Future Directions in Pharmacological Treatment for Amphetamine-Type Stimulant Use Disorder
  10. What Psychiatrists Should Know About Prescribed Safer Opioid Supply
  11. Postdischarge Mortality in a Cohort Hospitalized With Anorexia Nervosa
  12. Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
  13. Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review
  14. Associations between Gender Expression, Protective Coping Strategies, Alcohol Saliency, and High-Risk Alcohol Use in Post-Secondary Students at Two Canadian Universities
  15. Associations between Gender Expression, Protective Coping Strategies, Alcohol Saliency, and High-Risk Alcohol Use in Post-Secondary Students at Two Canadian Universities
  16. Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
  17. Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited
  18. Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders
  19. Implications of Cannabis Legalization on Substance-Related Benefits and Harms for People Who Use Opioids: A Canadian Perspective
  20. Cannabis use disorder and adverse cardiovascular outcomes: A population‐based retrospective cohort analysis of adults from Alberta, Canada
  21. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
  22. Ketamine for the treatment of major depression: a systematic review and meta-analysis
  23. Ways to get a more balanced gender representation in addiction journals’ management and workforce
  24. Cases: Multiorgan failure in a 38-year-old man with recent consumption of kratom, an atypical opioid
  25. The Effectiveness of Inpatient Addiction Consult Services: A Systematic Review and Narrative Synthesis
  26. Guilty until proven innocent
  27. Assessing research competency development in Canadian psychiatry residency programs: A systematic review and future directions
  28. Association Between Substance Use and Professional Outcomes Among Medical Students: Findings from a Canadian Cross-sectional Survey
  29. Managing Comorbid Tobacco Use Disorder for Individuals With Schizophrenia: Challenges and Opportunities
  30. Letter to the Editor: Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?
  31. Psychological interventions for post-traumatic stress injuries among public safety personnel: a systematic review and meta-analysis
  32. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis
  33. The Rising Tide of Stimulant-Related Morbidity and Mortality Warrants Evidence-Based Treatment
  34. The critical role of peer reviewers: Challenges and future steps
  35. Factors Associated With Past-year and Lifetime Prevalence of Cannabis Withdrawal: A Secondary Analysis
  36. Trends in Canadian Cannabis Consumption Over Time: A Two-step Meta-analysis of Canadian Household Survey Data
  37. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis
  38. Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review
  39. Neurobiology and Symptomatology of Post-Acute Alcohol Withdrawal: A Mixed-Studies Systematic Review
  40. Exclusion of the non-English-speaking world from the scientific literature: Recommendations for change for addiction journals and publishers
  41. Challenges and opportunities for further research involving the cannabis‐to‐opioid use transition
  42. Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study
  43. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta‐analysis
  44. Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review
  45. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
  46. Comment on “I’m Virtually a Psychiatrist: Problems with Telepsychiatry in Training”
  47. Patients With Infective Endocarditis Deserve Evidence-based Addiction Treatment
  48. Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders
  49. The Prevalence of Impulse Control Disorders and Behavioral Addictions in Eating Disorders: A Systematic Review and Meta-Analysis
  50. Considering Cannabis Use in Differential Diagnosis
  51. Listening to the Patient's Voice: A Patient-Centred Approach to Treatment-Resistant Schizophrenia
  52. The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis
  53. Prevalence of and Factors Associated With Substance Use Among Canadian Medical Students
  54. What are the clinical implications of Bahá’í perspectives of psychiatry and mental health?
  55. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis
  56. Genetic markers of the stress generation model: A systematic review
  57. Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis
  58. Concurrent Disorders Management in Psychiatric Care: Opportunities and Challenges
  59. The Prevalence of Cannabis Use Disorder Comorbidity in Individuals With Bipolar Disorder: A Systematic Review and Meta-Analysis
  60. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
  61. Supporting Persons Who Use Drugs During the COVID-19 Pandemic: A Rapid Review of International Guidelines
  62. Towards competency-based medical education in addictions psychiatry: a systematic review
  63. Ketamine for Bipolar Depression: A Systematic Review
  64. Proactive psychological programs designed to mitigate posttraumatic stress injuries among at-risk workers: a systematic review and meta-analysis
  65. Comparative Efficacy and Acceptability of Psychotherapies for Self-harm and Suicidal Behavior Among Children and Adolescents
  66. Making a case for the inclusion of refractory and severe mental illness as a sole criterion for Canadians requesting medical assistance in dying (MAiD): a review
  67. Misuse and dependence of dimenhydrinate: A mixed studies systematic review
  68. Transcranial direct current stimulation for empathy: A systematic review and meta-analysis
  69. Psychological interventions for posttraumatic stress injuries among public safety personnel: a systematic review and meta-analysis
  70. Coping among public safety personnel: A systematic review and meta–analysis
  71. Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
  72. Policy Brief: CSAM in Support of the Decriminalization of Drug Use and Possession for Personal Use
  73. Recent Advances in Biomarkers of Addiction: A Narrative Review
  74. Erratum to “Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis” [Journal of Affective Disorders 278C (2021) 542–555]
  75. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
  76. Response to Canadian Psychiatric Association Cannabinoid Products Position Statement: Potential for Ameliorating Cannabis Withdrawal
  77. Alcohol-Related Psychiatric Presentations at a University-Affiliated Emergency Department: A Descriptive Prevalence Study
  78. Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis
  79. COVID-19 and the Need for Leadership Training in Psychiatry
  80. The Substance Treatment and Recovery Team (START): Measuring the effectiveness and feasibility of an inpatient addiction consult service at an academic general hospital
  81. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis
  82. The Addictive Nature of Compulsive Sexual Behaviours and Problematic Online Pornography Consumption: A Review
  83. Response to Canadian Psychiatric Association Opioid Use Disorder Position Statement: More than Just Collaborators in Care
  84. The Impact of Community Treatment Orders on Substitute Decision Makers
  85. Predictors of hospital admission for patients presenting with psychiatric emergencies: A retrospective, cohort study
  86. Virtual psychiatric care for older adults in the age of COVID‐19: Challenges and opportunities
  87. How to Serve the Underserved: Making the Case for Rural and Remote Mental Health Training for Psychiatry Residents
  88. Harm Reduction for Injection Drug Users with Infective Endocarditis: A Systematic Review
  89. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis
  90. Effectiveness of Pharmacotherapies for Bipolar Depression: A Systematic Review & Network Meta-Analysis
  91. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids
  92. Incidence and Correlates of Cannabinoid-Related Psychiatric Emergency Care: A Retrospective, Multiyear Cohort Study
  93. Methamphetamine-Related Emergency Department Visits Requiring Psychiatric Admission: A Retrospective Cohort Study
  94. Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis
  95. Commentary on Hayes et al. (2020): The harms of opioid dose escalation in the management of chronic non‐cancer pain
  96. Acknowledgement to Reviewers of JCM in 2019
  97. Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis
  98. Systematic Review and Meta-Analyses of Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Reply to the Commentary by Jørgensen, Storebø, and Simonsen
  99. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis
  100. Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
  101. Prevalence of intimidation, harassment, and discrimination in resident physicians: a systematic review and meta-analysis
  102. At-a-glance - The local response to the Canadian opioid epidemic in the Kingston, Frontenac, and Lennox and Addington communities
  103. 2.62 PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADOLESCENTS WITH SUBCLINICAL AND BORDERLINE PERSONALITY DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
  104. Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Systematic Review and Meta-Analysis
  105. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta‐analysis
  106. International Perspectives on the Implications of Cannabis Legalization: A Systematic Review & Thematic Analysis
  107. What are the key considerations for clinicians treating Bahá'í patients with psychiatric disorders?
  108. Commentary on Stockings et al . (2019): The global amphetamine epidemic — a rising tide of mortality
  109. The Value of Hospitalization in the Opioid Epidemic
  110. Is stigma preventing knowledge translation and utilization of electroconvulsive therapy for depression?
  111. Management of endocarditis among persons who inject drugs: A narrative review of surgical and psychiatric approaches and controversies
  112. Piloting an Addictions Medicine Consultation Team in Kingston, Ontario, Canada
  113. Prevalence of substance use disorder comorbidity among individuals with eating disorders: A systematic review and meta-analysis
  114. Characterizing inpatient care for adults with schizophrenia using the Health Quality Ontario indices: A single-centre retrospective cohort study
  115. A Critical Review of Addictions Curriculum in Canadian Residency Programs
  116. ECT beyond unipolar major depression: systematic review and meta‐analysis of electroconvulsive therapy in bipolar depression
  117. The Emerging Epidemic of Male Me-Too
  118. Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents
  119. Assessing the utility of drug screening in the emergency: a short report
  120. Episodic Behavioural Regression in an 8-Year-Old Female: Sequelae of 22q11.2 Duplication Syndrome
  121. A case for opioid education and training for medical students, residents, and allied health staff: response to “educational intervention for physicians to address the risk of opioid abuse”
  122. Endocarditis in the setting of IDU
  123. Opioids on Trial
  124. Why residents need more training in prescribing antipsychotics for people with Schizophrenia
  125. Increasing awareness about HIV prevention among young people who initiated injection drug use in a Canadian setting, 1988–2014